Browsing by Author "Orellana, Paulina"

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Biomarkers for dementia in Latin American countries: Gaps and opportunities
    (2023) Parra, Mario A.; Orellana, Paulina; Leon, Tomas; Victoria, Cabello G.; Henriquez, Fernando; Gomez, Rodrigo; Avalos, Constanza; Damian, Andres; Slachevsky, Andrea; Ibanez, Agustin; Zetterberg, Henrik; Tijms, Betty M.; Yokoyama, Jennifer S.; Pina-Escudero, Stefanie D.; Cochran, J. Nicholas; Matallana, Diana L.; Acosta, Daisy; Allegri, Ricardo; Arias-Suarez, Bianca P.; Barra, Bernardo; Behrens, Maria Isabel; Brucki, SoniaM. D.; Busatto, Geraldo; Caramelli, Paulo; Castro-Suarez, Sheila; Contreras, Valeria; Custodio, Nilton; Dansilio, Sergio; De la Cruz-Puebla, Myriam; de Souza, Leonardo Cruz; Diaz, Monica M.; Duque, Lissette; Farias, Gonzalo A.; Ferreira, Sergio T.; Guimet, Nahuel Magrath; Kmaid, Ana; Lira, David; Lopera, Francisco; Meza, Beatriz Mar; Miotto, Eliane C.; Nitrini, Ricardo; Nunez, Alberto; O'Neill, Santiago; Ochoa, John; Pintado-Caipa, Maritza; Resende, Elisa de Paula Franca; Risacher, Shannon; Rojas, Luz Angela; Sabaj, Valentina; Schilling, Lucas; Sellek, Allis F.; Sosa, Ana; Takada, Leonel T.; Teixeira, Antonio L.; Unaucho-Pilalumbo, Martha; Duran-Aniotz, Claudia
    Limited knowledge on dementia biomarkers in Latin American and Caribbean (LAC) countries remains a serious barrier. Here, we reported a survey to explore the ongoing work, needs, interests, potential barriers, and opportunities for future studies related to biomarkers. The results show that neuroimaging is the most used biomarker (73%), followed by genetic studies (40%), peripheral fluids biomarkers (31%), and cerebrospinal fluid biomarkers (29%). Regarding barriers in LAC, lack of funding appears to undermine the implementation of biomarkers in clinical or research settings, followed by insufficient infrastructure and training. The survey revealed that despite the above barriers, the region holds a great potential to advance dementia biomarkers research. Considering the unique contributions that LAC could make to this growing field, we highlight the urgent need to expand biomarker research. These insights allowed us to propose an action plan that addresses the recommendations for a biomarker framework recently proposed by regional experts.
  • Thumbnail Image
    Item
    Differential expression profile of CXCR3 splicing variants is associated with thyroid neoplasia. Potential role in papillary thyroid carcinoma oncogenesis?
    (2018) Urra, Soledad; Fischer, Martin C.; Martinez, Jose R.; Veliz, Loreto; Orellana, Paulina; Solar González, Antonieta Alejandra; Bohmwald Prieto, Karen; Kalergis Parra, Alexis Mikes; Riedel, Claudia; Corvalán R., Alejandro; Roa Strauch, Juan Carlos Enrique; Fuentealba, Rodrigo; Cáceres, C. Joaquín; López Lastra, Marcelo Andrés; León Ramírez, Augusto; Droppelmann, Nicolás; Gonzalez, Hernan E.
  • Thumbnail Image
    Item
    EGFR pathway subgroups in Chilean colorectal cancer patients, detected by mutational and expression profiles, associated to different clinicopathological features
    (2017) Alvarez, Karin; Orellana, Paulina; Villarroel, Cynthia; Contreras, Luis; Kawachi, Hiroshi; Kobayashi, Maki; Wielandt, Ana María; De la Fuente, Marjorie; Triviño, Juan Carlos; Carvallo de Saint Quentin, Pilar; Kronberg, Udo; López-Köstner, Francisco
  • Thumbnail Image
    Item
    Lynch syndrome: selection of families by microsatellite instability and immunohistochemistry
    (SOC MEDICA SANTIAGO, 2012) Maria Wielandt, Ana; Zarate, Alejandro J.; Hurtado, Claudia; Orellana, Paulina; Alvarez, Karin; Pinto, Eliana; Contreras, Luis; Corvalan, Alejandro; Kronberg, Udo; Lopez Koestner, Francisco
    Background: Selection of patients with Lynch Syndrome (LS) for a genetic study involves the application of clinical criteria. To increase the rate of identification of mutations, the use of molecular studies as Microsatellite Instability (MSI) and Immunohistochemistry (IHC) in the tumor has been proposed. Aim: To demonstrate the usefulness of MSI and IHC in the detection of mutations in patients with LS. Material and Methods: From our Familial Colorectal Cancer Registry, families suspected of LS were selected according to Amsterdam or Bethesda clinical criteria. Screening of germline mutations of MLH1, MSH2 and MSH6 genes was performed. In addition, analysis of MS I and IHC were performed in colorectal tumors. Results: A total of 35 families were studied (19 met Amsterdam and 16 met Bethesda criteria). Twenty one families harbored a germline alteration in MLH1, MSH2 or MSH6 (18 Amsterdam and 3 Bethesda). In these families, eighteen different alterations were found, 15 of which were mutations and 3 corresponded to variants of uncertain pathogenicity. On the other hand, 80% of the tumors showed positive microsatellite instability (27 MSI-high and 1 MSI-low), and immunohistochemical testing showed that 77% of tumors had the loss of a protein. Correlation between results of tumor molecular studies and the finding of germline nucleotide change showed that IHC and MSI predicted mutations in 81 and 100% of patients, respectively. Conclusions: MSI and IHC can efficiently select patients with a high probability of carrying a mutation in DNA repair genes. (Rev Med Chile 2012; 140: 1132-1139).